Clinical trials: Primary Headache
Migraine
MK3207 for Treatment of Acute Migraines (3207-005)
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
- Trial name
- NCT00712725
- Testing
- MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg
- Volunteers
- 676 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Headache
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
The purpose of this study is to evaluate the safety and efficacy of MK-6096 versus placebo for preventing migraines in participants with episodic migraine.
- Trial name
- NCT01513291
- Testing
- MK-6096
- Volunteers
- 237 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
The purpose of this pilot study is to assess feasibility and clarify the design of future study(ies) to support marketing approval of the GammaCore™ device for the treatment and/or prevention of migraine symptoms.
- Trial name
- NCT01532830
- Testing
- n-VNS
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- ElectroCore INC
Migraine
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®.
- Trial name
- NCT00203307
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Thomas Jefferson University
Migraine
Staccato Loxapine in Migraine (in Clinic)
The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in patients with migraine headache with or without aura in a clinical setting.
- Trial name
- NCT00489476
- Testing
- Staccato Loxapine
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine
Melatonin for Adolescent Migraine Prevention Study
This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2 different dosing arms) vs. placebo for migraine prevention in adolescents.
- Trial name
- MAP (NCT03150797)
- Testing
- Melatonin
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Amy Gelfand
Migraine
Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches
Cranial electrotherapy stimulation (CES) may be a safe adjunct to medical treatment for pain relief in migraine patients. However, despite the number of CES studies done, many have been open label, single blinded, or have…
- Trial name
- NCT01265797
- Testing
- Cranial Electrostimulator
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Toledo Health Science Campus
Migraine
Treximet Early Intervention Adolescent Migraine
The study involves approximately 105 adolescent (ages 12-17) subjects to be screened at 4 sites across the US. All subjects enrolled will treat up to 4 MILD migraines over a 6 month period.
- Trial name
- TEAM (NCT01016678)
- Testing
- Treximet
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Premiere Research Institute
Migraine
Ictal and Interictal Inflammatory Markers in Migraine
The purpose of this study is to evaluate blood levels of several proteins that may be altered in the inflammation associated with migraine headaches.
- Trial name
- NCT01138150
- Testing
- Treximet
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Johns Hopkins University
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Migraine, Episodic Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
- Trial name
- CHALLENGE-MIG (NCT05127486)
- Testing
- Galcanezumab, Rimegepant
- Where
- 77 sites in United States
- Volunteers
- 580 people
- Sponsor
- Eli Lilly and Company
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
- Trial name
- ARISE (NCT02483585)
- Testing
- Erenumab
- Where
- 76 sites in United States, Denmark and 6 more
- Volunteers
- 577 people
- Sponsor
- Amgen
Migraine, Tension-type Headache
Comparing Naproxen to Sumatriptan for Emergency Headache Patients
2/3 of patients discharged from an emergency department after treatment for an acute headache will still be bothered by headache within 24 hours of emergency department (ED) treatment.
- Conditions
- Migraine, Tension-type Headache, Primary Headache Disorder
- Trial name
- HEDNet2 (NCT00449787)
- Testing
- Sumatriptan 100 mg, Naproxen
- Where
- 2 sites in United States
- Volunteers
- 401 people
- Sponsor
- Montefiore Medical Center
Migraine Disorders
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen sodium) in adolescents for the acute treatment of migraine.
- Trial name
- NCT00488514
- Testing
- Combination Tablet of Treximet (sumatriptan/naproxen sodium)
- Where
- 77 sites in United States
- Volunteers
- 656 people
- Sponsor
- GlaxoSmithKline
Migraine
A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
The purpose of this study is to assess the efficacy (headache freedom at 2 hours) of Timolol 0.5% ophthalmic solution compared to placebo in acute treatment of migraine headache.
- Trial name
- NCT03836664
- Testing
- Timolol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Acute Migraine
Valproate Versus Ketorolac Versus Metoclopramide
This randomized study is testing 3 different intravenous medications to see which one is best for acute migraine. The three medications are metoclopramide, valproate, and ketorolac.
- Trial name
- NCT01267864
- Testing
- Metoclopramide, Ketorolac, Valproate
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- Montefiore Medical Center
Migraine
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody…
- Trial name
- NCT04294147
- Testing
- Galcanezumab, Erenumab
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals